REG-Biocompatibles Intl.: Interim Management Statement

4 November 2009

BIOCOMPATIBLES INTERNATIONAL PLC

("Biocompatibles" or the "Company")

Interim Management Statement

Farnham UK, 4 November 2009: Biocompatibles International plc (LSE:BII) is
pleased to publish its Interim Management Statement ("IMS") relating to the
three month period ended 30 September 2009. The IMS covers information up to 3
November 2009.

Financial update

Sales were ahead of expectations during the period and the Company now expects
full year revenue to be around the upper end of the guidance that was
increased, on 26 August 2009, to £24m - £26m. This revised range reflects
revenue growth of 36% to 47% on the 2008 financial year.

The Company generated £2.3m of net funds during the period closing with £31.8m
as of 30 September. This was as a result of receiving the £3m milestone payment
from Eisai Co. Ltd. ("Eisai"), as described below. The year end guidance for
closing net funds was increased to £28m on 26 August 2009 and the Company now
expects to exceed this figure.

Operational update

On 28 July 2009, the Company announced that Eisai exercised its option to
license Biocompatibles' DC Bead™ and PRECISION Bead™ products in Japan. This
delivered Bicompatibles an initial up-front licence fee of £3m in September
2009, and is expected to be followed by further milestone payments based on
Eisai's achievement of various commercial and regulatory targets over the next
few years. If regulatory approval is obtained, Biocompatibles will supply Eisai
with manufactured products at cost and will receive a double-digit royalty on
net sales.

On 7 August 2009 the Company reported the announcement made by our distribution
partner for China, SciClone Pharmaceuticals, Inc., ("SciClone") that a small
local trial was required for regulatory approval in China and that SciClone now
expects to receive regulatory approval for DC Bead™ in the second half of 2010.
The Company had originally hoped to launch the DC Bead in China in 2009.

Commenting on the third quarter of 2009, Crispin Simon, Chief Executive of
Biocompatibles said: "The Company's operational and financial progress,
reported in our Interim Results has continued in the third quarter and we are
positioned well for a good second half to the year."

Contact:

Biocompatibles +44 (0) 1252 732706

Crispin Simon, Chief Executive

Ian Ardill, Finance Director

Anna Keeble +44 (0)7879 818876

Julian Walker +44 (0)20 7357 9477

Biocompatibles International plc (www.biocompatibles.com)

Biocompatibles International plc is a leading medical technology company in the
field of drug-device combination products.

The Oncology Products Division supplies medical devices from facilities in
Farnham, UK and Oxford, CT. These include Drug-Eluting Bead Products which are
used in more than 35 countries for the treatment of primary liver cancer (HCC),
liver metastases from colorectal cancer, and other cancers; and Brachytherapy
products (Radiation-Delivering Seeds) which are used in the treatment of
prostate cancer. Our distribution partners include AngioDynamics Inc., Terumo
Corporation and Eisai Co. Ltd. We have a clinical collaboration agreement with
Bayer Healthcare Pharmaceuticals Inc.

Our Licensing Division includes CellMed, in Alzenau, Germany, which is
developing a Drug-Eluting Bead product for the treatment of stroke, based on
proprietary stem cell technology; a GLP-1 analogue for the treatment of
diabetes and obesity partnered with AstraZeneca; and a cosmetic Dermatology
Bead partnered with Merz Pharmaceuticals GmbH. We also have a PC Licensing
agreement with Medtronic Inc. in the field of Drug-Eluting Stents.

This news release contains forward-looking statements that reflect
Biocompatibles' current expectation regarding future events. Forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors
including the success of Biocompatibles' research strategy, the applicability
of the discoveries made therein, the successful and timely completion of
clinical studies and the uncertainties related to the regulatory and
commercialisation processes.

END